Skip to main content

Bar Harbor Biotech Closes 'Multi-Million-Dollar' VC Round; Plans Oct. 1 Product Launch

NEW YORK (GenomeWeb News) — Bar Harbor Biotechnology has closed a “multi-million dollar” round of Series A financing and plans to use the cash to market its first product, the company said Tuesday.
Bar Harbor Biotechnology, based in Trenton, Maine, is developing a suite of gene-expression products that includes bioanalysis software, qPCR arrays, and bioinformatics applications for gene-expression experiments.
Bar Harbor, which spun off from the Jackson Laboratory in 2006, said it plans to launch its first commercial product on Oct. 1. It was not immediately clear what that product will be.
Leading the investment round was Borealis Ventures, a seed capital company based in Hanover, NH, that focuses on New England startups. Village Ventures, an early-stage investment specialist based in Williamstown, Mass., contributed to the round.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.